ストックスクリーナーアプリを入手
0.2578
6.84%
0.0165
アフターアワーズ：
.25
-0.0078
-3.03%
前日終値:
$0.2413
開ける：
$0.2426
24時間の取引高:
591.57K
Relative Volume:
0.37
時価総額：
$2.34M
収益：
$852.30K
当期純損益:
$-21.37M
株価収益率:
-0.0119
EPS:
-21.6981
ネットキャッシュフロー:
$-19.06M
1週間 パフォーマンス:
-10.05%
1か月 パフォーマンス:
-38.40%
6か月 パフォーマンス:
-79.86%
1年 パフォーマンス:
-98.27%
1日の値動き範囲:
$0.226
$0.2598
1週間の範囲:
$0.226
$0.30
52週間の値動き範囲:
$0.226
$15.75
Geovax Labs Inc Stock (GOVX) Company Profile
Compare GOVX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
0.2578 | 2.34M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-04-15 | 繰り返されました | Alliance Global Partners | Buy |
| 2025-04-15 | 繰り返されました | D. Boral Capital | Buy |
| 2024-11-11 | 開始されました | Alliance Global Partners | Buy |
| 2024-07-16 | 開始されました | ROTH MKM | Buy |
| 2020-11-19 | 開始されました | Maxim Group | Buy |
すべてを表示
Geovax Labs Inc (GOVX) 最新ニュース
GeoVax Labs, Inc. SEC Filing (Sep 24, 2026) - Stock Titan
GeoVax Labs Inc (NASDAQ: GOVX) Share Price, GOVX Stock News, GOVX Share Price & Updates - kalkine.ca
GeoVax Labs, Inc. New (GOVX) Total Assets 2025: $6.3M, down 22.2% - Stock Titan
GeoVax Labs (NasdaqCM:GOVX) Stock Forecast & Analyst Predictions - Simply Wall Street
GeoVax Sets October 13 Nasdaq Hearing on Delisting Appeal - minichart.com.sg
GeoVax provides Nasdaq hearing update, plans to present compliance plan and advance GEO-MVA Phase 3 - TradingView
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities - TradingView
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities - Yahoo! Finance Canada
GeoVax Welcomes Global Mpox Vaccine Stockpile, Highlights GEO-MVA's Role in Diversifying Supply - citybuzz -
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply - TradingView
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply - ca.finance.yahoo.com
GeoVax (NASDAQ: GOVX) plans reverse split after Nasdaq delisting notice - Stock Titan
GeoVax Labs (NASDAQ: GOVX) Secures $3.65M from Warrant Exercise, Issues 11.4M New Warrants at $0.64 - Kalkine Media
GeoVax Labs Inc. Warrants (GOVXW) Key Financial Ratios – Valuation, Profitability & More - Value Research
GeoVax Labs (GOVX) Holds Near $0.72 as Stock Consolidates Within Key Trading RangeInitial Balance - dars.gov.et
GeoVax Labs (GOVX) Holds Near $0.72 as Stock Consolidates Within Key Trading RangeCounter Trend Trade - dars.gov.et
GeoVax Raises $3.6M in Warrant Inducement, Issues 11.4M New Warrants - Minichart
GeoVax Raises $3.65M Via Warrant Exercise, Issues 11.4M New Warrants at $0.64 - TradingView
GeoVax Labs (GOVX) swaps $3.6M now for future warrant upside - Stock Titan
GeoVax Labs Inc. (GOVX) Peer Comparison – Compare with Others - Value Research
GeoVax Labs Inc. (GOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
GeoVax Announces a Warrant Inducement Transaction - Yahoo Finance
GeoVax Announces a Warrant Inducement Transaction - TradingView
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation - Yahoo Finance
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak - Yahoo Finance
GeoVax (GOVX) Quarterly Figures: EPS Lands Above Forecast; Post-Report: Shares Close 7.31% Higher in the Latest SessionSlow Growth Warning - vinanet.vn
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit - Yahoo Finance
GeoVax (GOVX) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.86% DownRevenue Estimate Trend - vinanet.vn
GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake - Stock Titan
GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants - Stock Titan
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak - Yahoo Finance
GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants - Stock Titan
GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply - TradingView
GeoVax Labs (GOVX) Dips 3.38% to $0.74, Holding Above Key $0.70 SupportDaily Profile - Vinanet
GeoVax Labs (NASDAQ:GOVX): What Could Today’s program progress and financing needs Update Reveal? - Kalkine Media
GeoVax Labs, Inc. (GOVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Proactive financial news
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase - Yahoo Finance
GeoVax Labs (GOVX) Dips 2.07% to $0.75 as Biotech Tests Key SupportConversion Trade - dars.gov.et
GeoVax Labs (GOVX) Dips 2.07% to $0.75 as Biotech Tests Key SupportETF Creation Redemption - vinanet.vn
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Proactive financial news
Jane Street Group discloses 4.3% GeoVax Labs (GOVX) ownership in updated 13G - Stock Titan
Health preparedness key as biological threats evolve - BioProcess International
GOVX Q2 2026 Earnings: Loss Narrower Than Expected Despite No RevenueBasic EPS Analysis - vinanet.vn
GOVX Q2 2026 Earnings: 66.98% EPS Surprise Lifts Shares 6.75%Post-Earnings Reaction - vinanet.vn
GeoVax Completes Key Milestones for GEO-MVA, Paving Way for Phase 3 Trial - citybuzz -
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Yahoo Finance
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Yahoo Finance
GeoVax Labs (GOVX) Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.97 Per ShareOne-Time Loss Impact - vinanet.vn
GeoVax Labs Inc (GOVX) Institutional Confidence - TradingKey
Geovax Labs Inc (GOVX) 財務データ
収益
当期純利益
現金流量
EPS
1.49%
大文字化:
|
ボリューム (24 時間):